ConforMIS

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers.

Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to Expand Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to Expand

Conformis Announces License Agreement with Paragon 28

BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time.

Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay. Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay.

Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants

ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ConforMIS (CFMS) Upgraded to Buy: Here's What You Should Know

Conformis, Inc. (CFMS) CEO Mark Augusti on Q4 2020 Results - Earnings Call Transcript

ConforMIS (CFMS) delivered earnings and revenue surprises of 27.27% and -0.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q4 Loss, Misses Revenue Estimates

BILLERICA, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the fourth quarter and year ended December 31, 2020.

Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results

Shares of ConforMIS (NASDAQ: CFMS) traded up as high as 37% in Tuesday's pre-market trading session. The company released a press release stating that the Therapeutic Goods Administration, part of the Australian Department of Health, cleared ConforMIS's total knee replacement system.

ConforMIS Spikes On Australian Approval News

On Wednesday, March 03, Conformis (NASDAQ:CFMS) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Conformis's Earnings Outlook

CFMS stock is jumping as Conformis preps to introduce a knee replacement system in Australia. Here's what you should know.

CFMS Stock: Why Under-the-Radar Conformis Is on the Move

The stock price of ConforMIS Inc (NASDAQ: CFMS) is trading at over 50% pre-market as of 4:48 AM ET. This is why it happened.

CFMS Stock Price Increases Over 50% Pre-Market: Why It Happened

The iTotal® PS total knee replacement system is designed so that its patient-specific implants fit the unique size and shape of each patient's knee, and provide optimal stability throughout the full range of motion The iTotal® PS total knee replacement system is designed so that its patient-specific implants fit the unique size and shape of each patient's knee, and provide optimal stability throughout the full range of motion

Conformis, Inc. Announces Clearance in Australia for iTotal® PS, the Only Personalized, Posterior-Stabilized Total Knee Replacement System

BILLERICA, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its common stock at an offering price of $1.05 per share. The gross proceeds from the offering will be approximately $85 million, before deducting underwriting discounts and commissions and estimated offering expenses. The closing of the offering is expected to take place on February 17, 2021, subject to the satisfaction of customary closing conditions.

Conformis, Inc. Announces Pricing of $85 Million Underwritten Offering of Common Stock

BILLERICA, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced that it intends to offer shares of its common stock in an underwritten public offering. Conformis intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover over-allotments in the sales of the shares, if any. All of the shares of common stock will be offered by Conformis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Conformis, Inc. Announces Proposed Public Offering of Common Stock

BILLERICA, Mass. and COLUMBIA CITY, Ind., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply agreement. The companies will work together to incorporate SITES Medical's proprietary OsteoSync Ti Technology into future Conformis' cementless total knee replacement products.

Conformis, Inc. and SITES Medical Announce Development & Supply Agreement

Conformis (CFMS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Conformis (CFMS) Looks Good: Stock Adds 7.7% in Session

Cordera™ Match Hip System combines the proven Cordera™ hip stem with Conformis' state-of-the-art, personalized pre-operative plans and patient-specific instruments. Cordera™ Match Hip System combines the proven Cordera™ hip stem with Conformis' state-of-the-art, personalized pre-operative plans and patient-specific instruments.

Conformis Announces U.S. Commercial Launch of Cordera™ Match Hip System

BILLERICA, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will participate in the 32nd Annual 2020 Piper Sandler Virtual Healthcare Conference taking place December 1-3, 2020. Conformis will provide an investor presentation and will be available for virtual one-on-one meetings during the conference.

Conformis, Inc. to Participate in the 32nd Annual Piper Sandler Healthcare Conference

BILLERICA, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Bart Lagae as its new VP, International Sales & Marketing.

Conformis Announces Bart Lagae as VP, International Sales & Marketing; Inducement Grant Reported

Conformis's (CFMS) CEO Mark Augusti on Q3 2020 Results - Earnings Call Transcript

BILLERICA, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the third quarter ended September 30, 2020.

Conformis Reports Third Quarter 2020 Financial Results

Conformis (NASDAQ: CFMS) releases its next round of earnings this Wednesday, November 04. Get the latest predictions in Benzinga's essential guide to the company's Q3 earnings report.

Earnings Outlook for Conformis

BILLERICA, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will participate in the virtual 2020 Oppenheimer Fall MedTech Summit taking place Thursday, November 12, 2020, in one-on-one meetings.

Conformis, Inc. to Participate in the 2020 Oppenheimer Fall MedTech Summit

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Earnings Call to be Hosted on November 4, 2020 Earnings Call to be Hosted on November 4, 2020

News for ConforMIS Stock (CFMS)